A small study using an experimental drug designed to slow the progress of Alzheimer’s disease has proven to be quite successful, so far. CBS News reported that the drug, called IVIG, contains antibodies from people who don't have Alzheimer's. It appears that the drug attacks Amyloid, the plaque that is thought to damage the brain. At this time, the Amyloid plaque is considered the hallmark of Alzheimer's disease.
The study showed that IVIG actually halted the cognitive decline in some patients with diagnosed AD. Twenty-four patients were studied, with 11 showing a smaller decline than the group taking a placebo. However, four patients showed no decline.